Positron 3Q 2026: Revenue $102.67K, EPS ($0.03) — 10-Q Summary
Positron reported 3Q 2026 revenue of $102.67K, down 7.5% YoY, with net loss narrowing 6.9% to $971.98K. EPS remained at ($0.03). Service costs rose 34.0%, while G&A expenses fell 29.6%. The company plans to expand in nuclear cardiology and oncology. Cash position was $1.9M with $2.0M credit available.
How this was made
The 30-second read
Why it matters
The disclosed revenue decline and loss narrowing are likely to influence short‑term price action, especially among microcap traders.
Market read
Primary earnings disclosure for a microcap; relevant for traders monitoring small‑cap health‑tech stocks.
What to watch
Potential upside from upcoming PET-CT expansion plans not yet reflected in the numbers.
Background
Positron Corp filed its Form 10‑Q for Q3 2026, providing the first detailed financial snapshot for the quarter.
Ticker impact
Positron Corp reported Q3 2026 revenue of $102.67K, a 7.5% YoY decline, and a narrowed net loss.
likely pressure as the market prices in weaker revenue and continued loss
Quarterly earnings are the first public disclosure of these numbers; the decline in revenue outweighs the modest loss improvement.
Market effects
May signal softness in the niche medical imaging equipment sector.
Limited to U.S. microcap investors.
Low
Counterpoint
The loss narrowing could be a sign of improving cost discipline, offering a buying opportunity at depressed prices.
Key entities
- CompanyPositron Corp
Medical imaging equipment manufacturer reporting Q3 2026 results.
